STOCK TITAN

Crinetics (CRNX) director receives new RSU and stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Crinetics Pharmaceuticals director Camille L. Bedrosian reported receiving new equity awards. She was granted 5,925 restricted stock units representing rights to receive Common Stock, vesting 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual stockholder meeting, subject to continued board service.

She also received stock options for 9,730 shares of Common Stock at an exercise price of $35.87 per share, expiring on June 18, 2036, with the same vesting schedule. After these awards, she directly holds 22,225 shares of Common Stock and 9,730 options.

Positive

  • None.

Negative

  • None.
Insider Bedrosian Camille L
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 9,730 $0.00 --
Grant/Award Common Stock 5,925 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 9,730 shares (Direct, null); Common Stock — 22,225 shares (Direct, null)
Footnotes (1)
  1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Restricted stock units granted 5,925 units Grant of RSUs on June 18, 2026 with time-based vesting
Stock options granted 9,730 options Right to buy Common Stock, granted June 18, 2026
Option exercise price $35.87 per share Exercise price for 9,730 stock options
Option expiration date June 18, 2036 Expiration of granted stock options
Shares held after awards 22,225 shares Direct Common Stock ownership following the grants
Options held after awards 9,730 options Total options following this grant
restricted stock units financial
"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares..."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date..."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest financial
"with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual meeting of the Issuer's stockholders financial
"the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service..."
exercise price financial
"Stock Option (Right to Buy)... conversion_or_exercise_price: "35.8700""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bedrosian Camille L

(Last)(First)(Middle)
C/O CRINETICS PHARMACEUTICALS, INC.
6055 LUSK BOULEVARD

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026A5,925A$0(1)22,225D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$35.8706/18/2026A9,730 (2)06/18/2036Common Stock9,730$09,730D
Explanation of Responses:
1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
2. The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Remarks:
/s/ Tobin Schilke, as attorney-in-fact06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Crinetics Pharmaceuticals (CRNX) report for Camille L. Bedrosian?

Crinetics reported that director Camille L. Bedrosian received new equity awards, including 5,925 restricted stock units and options for 9,730 shares. These awards are tied to her continued service on the company’s board of directors and follow a time-based vesting schedule.

How many restricted stock units did Camille L. Bedrosian receive from Crinetics (CRNX)?

She received 5,925 restricted stock units representing the right to receive shares of Common Stock. These units will vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual meeting, assuming continued board service.

What are the terms of the stock options granted to Camille L. Bedrosian by Crinetics (CRNX)?

She was granted options for 9,730 shares of Common Stock at an exercise price of $35.87 per share. The options vest on the same schedule as the restricted stock units and expire on June 18, 2036, giving a long exercise window after vesting.

When do Camille L. Bedrosian’s Crinetics (CRNX) equity awards vest?

Both the restricted stock units and stock options vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual stockholder meeting. Vesting is conditioned on her continued service on Crinetics’ board through the vesting date.

How many Crinetics (CRNX) shares does Camille L. Bedrosian hold after this Form 4?

Following these awards, she directly holds 22,225 shares of Crinetics Common Stock, according to the Form 4. In addition, she holds stock options covering 9,730 shares, which become exercisable after the specified vesting conditions are satisfied.

Is Camille L. Bedrosian’s Crinetics (CRNX) transaction a purchase or a grant?

The Form 4 lists the transactions under code “A,” meaning a grant, award, or other acquisition. The filing describes them as restricted stock units and stock options granted in connection with her role on the board, rather than open-market share purchases.